[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

a study on Cancer, General Immunotherapy

Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at San Francisco, California
Dates
study started
estimated completion
Principal Investigator
Robert R Flavell, M.D., Ph.D.
Photo of Robert R Flavell
Robert R Flavell

Description

Summary

This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy and/or radiation therapy.

Official Title

Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Who Have Received or Are Expected to Receive Immunotherapy and/or Radiation Therapy

Details

This is an exploratory Phase 1, prospective study assessing the biodistribution and radiation dosimetry of the Positron Emission Tomography [18F]FAraG (VisAcT) in cancer patients selected for immunotherapy and/or radiation therapy. Each patient may have up to two [ 18F]FAraG PET imaging sessions, a baseline scan and a post start of immunotherapy scan. For each imaging session, patients will receive a single injection of [18F]FAraG and undergo a whole-body PET scans an hour after injection of the tracer. Following each imaging session, the patient will be called within 72 hours to note any side effects.

Optional - Blood samples may be collected at up to 9 time points post-injection to analyze whole-blood/plasma time activity of [18F]FAraG in addition an urine sample may be collected post scan.

Keywords

Cancer [18F]F-AraG

Eligibility

You can join if…

Open to people ages 18-65

  • Cancer patients with identified tumor mass
  • Cancer patients expected to undergo immunotherapy and/or radiation therapy

You CAN'T join if...

  • Under the age of 18
  • Pregnant women
  • Women who are breastfeeding
  • Individuals with known or suspected substance abuse
  • Individuals unable or unwilling to comply with the study procedures

Location

  • UCSF Imaging Center at China Basin accepting new patients
    San Francisco California 94107 United States

Lead Scientist at UCSF

  • Robert R Flavell, M.D., Ph.D.
    Robert Flavell, MD, PhD, is the Chief of Molecular Imaging and Therapeutics Clinical Section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He received his medical degree from Weill Cornell Medical College, and his PhD from the Rockefeller University as part of the Tri-Institutional MD PhD program.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
CellSight Technologies, Inc.
ID
NCT03142204
Phase
Phase 1
Study Type
Interventional
Last Updated
Contact us about this trial